Loading clinical trials...
Loading clinical trials...
SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE
Conditions
Interventions
Upadacitinib
Placebo
Locations
369
United States
AZ Arthritis and Rheumatology /ID# 261848
Chandler, Arizona, United States
AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 254767
Flagstaff, Arizona, United States
Arizona Arthritis & Rheumatology Research, PLLC /ID# 252820
Gilbert, Arizona, United States
Arizona Arthritis and Rheumatology Research - Glendale Office /ID# 252824
Glendale, Arizona, United States
Arizona Arthritis & Rheumatology Research, PLLC /ID# 261845
Mesa, Arizona, United States
Arizona Arthritis & Rheumatology Research /ID# 273555
Peoria, Arizona, United States
Start Date
July 19, 2023
Primary Completion Date
March 1, 2027
Completion Date
October 1, 2027
Last Updated
March 12, 2026
NCT06875960
NCT06335979
NCT06647069
NCT07371468
NCT06333483
NCT07219563
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions